Reuters logo
3 months ago
BRIEF-Amag says first patient enrolled in phase 2b/3a digoxin immune fab study
June 1, 2017 / 12:20 PM / 3 months ago

BRIEF-Amag says first patient enrolled in phase 2b/3a digoxin immune fab study

June 1 (Reuters) - Amag Pharmaceuticals Inc

* Amag announces first patient enrolled in phase 2b/3a digoxin immune fab study conducted by velo bio

* Amag pharmaceuticals -believes results of dif study may form basis for new drug application with potential approval by u.s. Fda in 2020, assuming submission in 2019 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below